Overview

TNF and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

Status:
RECRUITING

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.

Phase:

PHASE1

Details

Lead Sponsor:

TILT Biotherapeutics Ltd.

Treatments:

Cyclophosphamide
fludarabine
fludarabine phosphate